Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab plus Enzalutamide in mCRPC (KEYNOTE-641)
NCT03834493Phase 3Terminated
- Sponsor
- Merck & Co.
- Start
- Jul 2019
- Primary completion
- Dec 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 28
01
Overview
Phase 3, randomised, double-blind trial in metastatic castration-resistant prostate cancer (mCRPC) comparing Pembrolizumab + Enzalutamide with Placebo + Enzalutamide (2 arms). Primary endpoints: Overall Survival up to 40 months and Radiographic Progression-free Survival up to 40 months. Started Jul 2019; status: terminated.
02
Drugs
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT03834493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03834493.